Agilent to Acquire Proscia for $240M, Expanding AI-Driven Pathology…

Event summary

Agilent Technologies Inc. to acquire Proscia for $240M in cash, with up to $30M in performance-based milestones.
Proscia's digital pathology software platform serves over 4,000 labs, hospitals, and clinics, and 16 of the top 20 pharmaceutical companies.
Proscia's Concentriq platform holds FDA 510(k) clearance for primary diagnosis and was named 2026 Best in KLAS for Digital Pathology.
The acquisition is expected to close early in Agilent’s fiscal year 2027, integrating Proscia into the Agilent Life Sciences and Diagnostics Markets Group.

The big picture

Agilent’s acquisition of Proscia strengthens its position in the digital pathology market, combining hardware and software capabilities to support AI-driven diagnostics and drug discovery. This move aligns with the broader industry trend towards digitalization and AI integration in pathology, enhancing Agilent’s offerings for both clinical and biopharma customers. The deal follows Agilent’s recent transaction with Biocare Medical, indicating a strategic focus on expanding its pathology portfolio.

What we're watching

Integration Challenges: How Agilent will merge Proscia’s vendor-agnostic digital pathology platform with its existing pathology instrumentation and reagents.
Market Expansion: Whether the acquisition will accelerate Agilent’s presence in the fast-growing $5 billion pathology market, particularly in AI-enabled workflows.
Financial Performance: The pace at which Proscia’s recurring-revenue model will contribute to Agilent’s long-term growth profile.